New Delhi: An expert panel of the Central Drugs Authority of India has recommended emergency use authorization to zydus cadillaSources said that the three-dose Kovid-19 vaccine is ZyCoV-D.
Subject Expert Committee (secondsThe Central Drugs Standard Control Organization (CDSCO) on Thursday discussed the application made by Zydus Cadila on COVID-19 and recommended emergency use authorization for its three-dose coronavirus vaccine.
recommendations have been sent drug controller General of India (DCGI) for final approval.
The Ahmedabad-based pharma major had applied for Emergency Use Authorization (EUA) with DCGI for the vaccine on July 1.
The company said that it has conducted the largest clinical trial for the vaccine so far in more than 50 centers in India.
If approved, ZyCoV-D will be the world’s first DNA vaccine against novel coronavirus infection to be developed by an Indian company and will become the sixth vaccine to be developed by Serum Institute’s Kovishield, Bharat Biotech’s Kovaxin, Russia. Sputnik V has since been approved for use in the country. and America-Made Moderna & Johnson & Johnson.
The plasmid DNA-based ZyCoV-D is to be administered intraperitoneally using a needle-free injector.
Sharvil Patel, managing director, Cadila Healthcare The U.S. had said that the vaccine, when approved, would help not only adults but also adolescents in the age group of 12 to 18 years.
Subject Expert Committee (secondsThe Central Drugs Standard Control Organization (CDSCO) on Thursday discussed the application made by Zydus Cadila on COVID-19 and recommended emergency use authorization for its three-dose coronavirus vaccine.
recommendations have been sent drug controller General of India (DCGI) for final approval.
The Ahmedabad-based pharma major had applied for Emergency Use Authorization (EUA) with DCGI for the vaccine on July 1.
The company said that it has conducted the largest clinical trial for the vaccine so far in more than 50 centers in India.
If approved, ZyCoV-D will be the world’s first DNA vaccine against novel coronavirus infection to be developed by an Indian company and will become the sixth vaccine to be developed by Serum Institute’s Kovishield, Bharat Biotech’s Kovaxin, Russia. Sputnik V has since been approved for use in the country. and America-Made Moderna & Johnson & Johnson.
The plasmid DNA-based ZyCoV-D is to be administered intraperitoneally using a needle-free injector.
Sharvil Patel, managing director, Cadila Healthcare The U.S. had said that the vaccine, when approved, would help not only adults but also adolescents in the age group of 12 to 18 years.
.